IMC Reports First Closing of the Panaxia Acquisition and Provides Update on Canadian Business Activities
IM Cannabis Corp. (CSE:IMCC, NASDAQ:IMCC) announced the first closing of its acquisition of Panaxia Pharmaceutical Industries, enhancing its online pharmacy and distribution capabilities in Israel. This strategic move is expected to boost IMC's market presence and operational efficiency. Additionally, the company launched its WAGNERS brand in Canada with new product offerings and achieved significant cultivation milestones, harvesting 8,000 plants in May 2021. IMC also completed a successful run-off of its loan portfolio, realizing a 24% internal rate of return.
- Acquisition of Panaxia enhances distribution and online pharmacy capabilities.
- Successful launch of WAGNERS brand expands product offerings in the Canadian market.
- Significant increase in cannabis cultivation, with an annualized production rate of 7,000 kg.
- None.
Launches WAGNERS brand with new cultivars and SKUs
MYM shareholder meeting set for July 5, 2021
Substantially completes loan portfolio run-off and realizes a
TORONTO, ON and GLIL YAM, ISRAEL / ACCESSWIRE / June 1, 2021 / IM Cannabis Corp. ("IMC" or the "Company") (CSE:IMCC), (NASDAQ:IMCC), a multi-country operator ("MCO") in the medical and adult-use recreational cannabis sector with operations in Israel, Germany and Canada, is pleased to provide the following update.
First Closing of the Panaxia Transaction
As announced on April 30th, the Company's fully owned Israeli subsidiary, IMC Holdings Ltd., signed a definitive agreement with Panaxia Pharmaceutical Industries Israel Ltd. and Panaxia Logistics Ltd., part of the Panaxia Labs Israel, Ltd. group of companies ("Panaxia") (TASE:PNAX), Israel's largest manufacturer of medical cannabis products, pursuant to which IMC will acquire Panaxia's trading house and in-house pharmacy activities. This agreement will combine its home-delivery services online pharmacy business operating under the name Panaxia to the Home and customer service center, along with certain distribution assets, and an option to purchase a pharmacy with licenses to sell medical cannabis to patients from Panaxia.
Panaxia to the Home currently stocks the largest medical cannabis products selection in Israel, which it offers to patients across the country through an online platform with temperature-controlled home delivery. Panaxia to the Home also operates a customer service center for patient support, as well as a team of skilled pharmacists who specialize in providing targeted counseling to patients on how best to use medical cannabis products. Upon the first closing announced today, all online-related activities and intellectual property are transferred to the Company, including, but not limited to, the online sales platform for medical cannabis products, a CRM platform and use of a large storage facility to support the operations of Panaxia to the Home.
"This is an important first step in the implementation of our Israeli retail strategy," said Oren Shuster, CEO of IMC. "The reason we started with the Panaxia acquisition is that its distribution spans nationwide across Israel. We are on track to realizing the Company's global revenue and margin potential through the expansion of its multi-country operating platform."
The second closing, which is subject to Israeli Ministry of Health ("MOH") approval, is expected to occur before July 30, 2021, or upon receipt of MOH approval.
* All figures are in $ CAD
Canadian Operations Update
Since the end of Q1 2021, Trichome JWC Acquisition Corp ("TJAC"), IMC's Canadian indirectly wholly owned subsidiary, has achieved numerous commercial and operational milestones:
- The formal launch of TJAC's new WAGNERS adult-use brand (link to website) has now begun. Following the successful soft launch in late Q1 2021, the WAGNERS brand continues its rollout, with products expected to be available in Ontario, BC, Alberta, Saskatchewan, New Brunswick, and PEI by the beginning of June.
- As part of the roll-out of the WAGNERS brand, TJAC has increased its offering of premium dried flower and pre-rolled SKUs to a total of four high-value strains, with a number of others launching in late 2021.
- In addition to new dried flower and pre-rolled offerings under the WAGNERS brand, TJAC is launching new concentrate SKUs, including a larger format Soap Bar Hash offered in 2g and 4g sizes, and an Afghani Soft Black Hash to be launched in Q2.
- Operationally, TJAC made significant strides in cultivation and processing. For May 2021, TJAC harvested 8,000 plants for the month, up from an average of 2,000 plants harvested per month in Q4 2020, on pace to an annualized production rate of approximately 7,000 kilograms of flower in the second half of 2021.
"The WAGNERS brand reflects our organization's culture, shared values and the principles of hard work and perseverance that are so evident in the surrounding Tri-Cities community," said Ross Hendry, Head of Sales & Marketing, TJAC. "We believe in delivering high quality product at a fair price, while being a better partner to our customers and over delivering for the consumer every day. The WAGNERS brand, sold through TJAC, is a great addition to IMC's portfolio as it extends our reach in the adult-use recreational market and advances our expansion strategy in the Canadian market."
Update on MYM Transaction
On April 1, 2021, the Company announced that it had entered into a definitive agreement (the "Arrangement Agreement") to acquire MYM Nutraceuticals Inc., (CSE: MYM) (OTCQB: MYMMF) ("MYM") and its licensed producer subsidiary, Highland Grow Inc ("Highland Grow"), pursuant to a plan of arrangement to be completed under the Business Corporations Act (British Columbia) (the "Transaction").
The Transaction was evaluated and recommended by an independent committee of directors of MYM (the "Special Committee"), who received independent financial and legal advice. In the arrangement agreement entered into in connection with the Transaction, the MYM board agreed with IMCC to include a recommendation in the circular to be mailed that MYM shareholders vote in favo r of the Transaction.
IMC has entered into voting support agreements with shareholders representing
Key dates with respect to the Transaction are as follows:
- May 31, 2021 - Record Date
- June 8, 2021 - Mailing of meeting materials to beneficial holders as of the Record Date
- June 30, 2021 - Proxy voting cutoff date
- July 5, 2021 - Shareholder meeting
- On or about July 7, 2021 - closing
Shareholders of MYM with questions regarding the Transaction can call toll-free (800) 232-0316 or email inquiries@dfking.com. Investors can also visit (link) to learn more about the benefits of the Transaction. Information regarding MYM and the Transaction is also available at www.sedar.com
Loan Portfolio Update
IMC is pleased to announce that its wholly-owned subsidiary, Trichome Financial Corp. ("TFC") has substantially completed the run-off of its loan portfolio, having received net cash proceeds of
TFC realized a weighted average internal rate of return of approximately
About IM Cannabis Corp.
IMC is an MCO in the medical and adult-use recreational cannabis sector, headquartered in Israel and with operations In Israel, Germany and Canada. Over the past decade, the Company believes that the IMC brand has become synonymous with quality and consistency in the Israeli medical cannabis market. The Company has also expanded its business to offer intellectual property-related services to the medical cannabis industry.
In Europe, IMC operates through Adjupharm GmbH ("Adjupharm"), a German-based subsidiary and EU GMP-certified medical cannabis processor and distributor. IMC's European presence is augmented by strategic alliances with various pan-European EU-GMP cultivators and distributors to capitalize on the increased demand for medical cannabis products in Europe and bring the IMC brand and its product portfolio to European patients.
In Canada, IMC operates through Trichome JWC Acquisition Corp. (d/b/a "JWC"). JWC is a licensed producer located in Kitchener, Ontario, selling cannabis flower, pre-rolls, hash and kief in the Canadian recreational cannabis market under the JWC and Wagners brands. JWC operates with high standards for providing clean, consistent, aeroponically-grown premium cannabis products to medical patients and the adult-use market throughout Canada and the world. On March 31, 2021, IMC entered into a definitive agreement to acquire MYM and its licensed producer subsidiary, Highland Grow Inc. This transaction, if completed, will reinforce IMC's goal of being a leading global premium cannabis producer and purveyor.
About Focus Medical Herbs Ltd.
Focus Medical is one of eight original licensed producers of medical cannabis in Israel and has over 10 years of experience growing high quality medical cannabis in the Israeli market. Focus Medical is an "investee" of the Company under IFRS (as defined below) due to the Company's "de facto control" over Focus Medical despite not having any direct or indirect ownership of it. Focus Medical has an exclusive commercial agreement with IMC to distribute its production under the IMC brand. In addition to its own capacity, Focus Medical has supply agreements with six other cultivators for additional supply using its proprietary genetics and for sale under the IMC brand.
Disclaimer for Forward-Looking Statements
This press release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian and United States securities laws (collectively, "forward-looking information"). Forward-looking information are often, but not always, identified by the use of words such as "seek," "anticipate," "believe," "plan," "estimate," "expect," "likely" and "intend" and statements that an event or result "may," "will," "should," "could" or "might" occur or be achieved and other similar expressions. Forward-looking information in this press release includes, without limitation, statements relating to plans regarding TJAC's future operations and brands, the completion of the acquisition of MYM, timing on the run-off of TFC's remaining loan portfolio and the Company's business and strategic plans.
Developing forward-looking information involves reliance on several assumptions and considerations of certain risks and uncertainties, some of which are specific to IMC and others that apply to the industry generally. Such assumptions include, but are not limited to, the ability of the Company to execute its business plans prior to and following the completion of the MYM Transaction; the continued growth of the medical and recreational cannabis markets in Israel, Canada, Germany and elsewhere in Europe; IMC maintaining "de facto" control over Focus Medical Herbs Ltd. ("Focus Medical") in accordance with IFRS 10; Focus Medical maintaining its existing Israeli cultivation license and other business permits in the State of Israel; the continuing strength and appeal of the IMC brand; future opportunistic acquisitions becoming available to the Company in the North American cannabis market and the expected legalization of adult-use recreational cannabis in Israel.
Risk factors and uncertainties, both known and unknown, could cause actual results to differ materially from the anticipated results or expectations expressed in this press release, include, without limitation: the ability of IMC to complete its acquisition of MYM on the terms contemplated or at all; the Company's ability to capture the benefits associated with its acquisition of Trichome Financial Inc. ("Trichome"); risks related to Trichome's lending operations; a resurgence in cases of COVID-19, which has occurred in certain locations and the possibility of which in other locations remains high and creates ongoing uncertainty that could result in restrictions to contain the virus being re-imposed or imposed on a more strict basis, including restrictions on movement and businesses; the extent to which COVID-19 impacts the global economy; the success of new COVID-19 workplace policies and the ability of people to return to workplaces; the Israeli government deciding to delay or abandon the legalization of adult-use recreational cannabis in Israel; the ability of the Company to comply with applicable government regulations in a highly regulated industry; unexpected changes in governmental policies and regulations affecting the production, distribution, manufacture or use of medical cannabis in Israel, Germany and other foreign jurisdictions in which the Company intends to operate; unexpected changes in governmental policies and regulations affecting the production, distribution, manufacture or use of adult-use recreational cannabis in Canada; engaging in activities considered illegal under United States federal law; risks of product liability and other safety-related liability as a result of usage of the Company's cannabis products; any failure of IMC to maintain "de facto" control over Focus Medical in accordance with IFRS 10; the Company and Focus Medical having to rely on third party cannabis producers to supply the Adjupharm and Focus Medical with product to successfully fulfill previously announced sales agreements and purchase commitments; the ability of Adjupharm and Focus Medical to deliver on their respective sales commitments; the risk that regulatory authorities in Israel may view IMC as the deemed owner of more than
Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
CONTACTS:
Oren Shuster
CEO, IM Cannabis Corp.
+972-77-3603504
info@imcannabis.com
Caitlin Kasunich
Media Relations - U.S.
+1 212-896-1241
ckasunich@kcsa.com
Gal Wilder
Media Relations - Canada
+1 416-602-4092
gwilder@cohnwolfe.ca
Elizabeth Barker
Investor Relations
+1 212-896-1203
ebarker@kcsa.com
SOURCE: IM Cannabis Corp.
View source version on accesswire.com:
https://www.accesswire.com/649884/IMC-Reports-First-Closing-of-the-Panaxia-Acquisition-and-Provides-Update-on-Canadian-Business-Activities
FAQ
What is the significance of the Panaxia acquisition for IM Cannabis Corp.?
What new products are being launched under the WAGNERS brand?
What were the results of IM Cannabis Corp.'s loan portfolio run-off?
What are the key dates for the MYM transaction?
